Aditxt, Inc. (ADTX)
NASDAQ: ADTX · Real-Time Price · USD
0.0915
-0.0273 (-22.98%)
At close: Feb 21, 2025, 4:00 PM
0.0919
+0.0004 (0.44%)
After-hours: Feb 21, 2025, 7:59 PM EST
Aditxt Employees
Aditxt had 47 employees as of December 31, 2023. The number of employees decreased by 14 or -22.95% compared to the previous year.
Employees
47
Change (1Y)
-14
Growth (1Y)
-22.95%
Revenue / Employee
$4,513
Profits / Employee
-$983,995
Market Cap
1.30M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 440,000 |
Johnson & Johnson | 131,900 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 72,000 |
ADTX News
- 1 day ago - Aditxt Subsidiary Pearsanta Engages Dominari Securities for its Initial Public Offering, to Drive U.S. and Global Commercial Launch of Early Cancer Detection and Diagnosis Targeted for H2 2025 - Business Wire
- 9 days ago - Aditxt to Host Fireside Chat on Friday, February 21st at 11:30 AM Eastern Time - Business Wire
- 5 weeks ago - Aditxt's Board of Directors Unanimously Approve Positioning Pearsanta for IPO to Support Global Launch of its Early Cancer Detection Platform - Business Wire
- 2 months ago - Aditxt's Subsidiary Adimune Successfully Completes Preclinical Efficacy and Safety Studies for Its Immune Modulation Therapeutic ADI Platform, Advancing Toward First-in-Human Clinical Trials - Business Wire
- 3 months ago - Evofem Biosciences Announces Financial Results for the Third Quarter of 2024 - PRNewsWire
- 3 months ago - Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares - Business Wire
- 3 months ago - Aditxt's Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders - Business Wire
- 3 months ago - Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem - Business Wire